Tesamorelin

What is Tesamorelin

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue developed specifically to address HIV-associated lipodystrophy syndrome. This 44-amino acid peptide differs significantly from other GHRH analogues like sermorelin or CJC-1295 due to its structural modification—a trans-3-hexenoic acid group attached to the N-terminus of GHRH(1-29). Research suggests this modification extends its half-life from minutes to 26-38 minutes whilst maintaining selectivity for visceral fat reduction.

Originally developed by Canadian firm Theratechnologies as TH9507, tesamorelin received FDA approval in 2010 under the brand name Egrifta for treating excess abdominal fat in HIV patients with lipodystrophy. However, it remains unlicensed by the MHRA in the UK, placing it in a regulatory grey area similar to other research peptides like BPC-157 and TB-500.

Tesamorelin Dosage and Administration

Clinical trials have established specific dosing protocols for tesamorelin, with the FDA-approved regimen being 2mg administered subcutaneously once daily. Studies indicate this dosage effectively stimulates growth hormone release whilst minimising side effects. Unlike direct growth hormone therapy or peptides such as MK-677, tesamorelin maintains the body's natural pulsatile GH release patterns.

Researchers typically administer tesamorelin in the evening to align with natural growth hormone secretion cycles. The peptide requires reconstitution similar to other injectable peptides—our reconstitution guide provides detailed protocols. Storage requirements mirror those of ipamorelin and other GHRH analogues, requiring refrigeration and careful handling as outlined in our peptide storage guidelines.

Tesamorelin Benefits and Clinical Evidence

The strongest clinical evidence supports tesamorelin's efficacy in reducing visceral adipose tissue. A pivotal Phase III trial published in The Lancet demonstrated a 15.2% reduction in visceral fat over 26 weeks in HIV patients with lipodystrophy. This selective fat reduction occurs without the broader metabolic disruptions associated with direct GH administration or growth hormone secretagogues like GHRP-6.

Beyond its approved indication, research suggests tesamorelin may benefit age-related body composition changes. Studies indicate improvements in insulin sensitivity and cardiovascular risk markers, making it distinct from purely cosmetic peptides like AOD-9604. The peptide's mechanism—stimulating endogenous GH and subsequent IGF-1 production—shares similarities with IGF-1 LR3 but maintains natural regulatory feedback loops.

Tesamorelin Side Effects and Safety Profile

Clinical trials report generally mild side effects with tesamorelin, primarily injection site reactions occurring in approximately 30% of patients. Unlike anabolic compounds or growth hormone therapy, tesamorelin rarely causes joint pain or fluid retention. However, as with other GH-stimulating peptides such as epithalon, careful monitoring is essential.

Common adverse events include mild injection site erythema, pruritus, and occasional nausea. Serious adverse events remain rare, with studies showing no increased cancer risk—a significant advantage over direct GH therapy. The peptide's selectivity for visceral fat suggests a more targeted mechanism compared to broad-spectrum compounds like semaglutide or tirzepatide.

UK Legal Status and Research Applications

In the UK, tesamorelin exists within the research peptide framework, similar to other investigational compounds available through verified suppliers. Whilst not MHRA-approved for therapeutic use, it remains legal for research purposes under current regulations detailed in our UK peptide legality guide.

Researchers utilise our cost calculator and stack builder tools to plan protocols involving tesamorelin alongside other research compounds. The peptide's unique selectivity profile makes it valuable for studying targeted fat reduction mechanisms, particularly when compared to general metabolic modulators like MOTS-C or SS-31.

Tesamorelin functions as a synthetic analogue of growth hormone-releasing hormone, binding specifically to GHRH receptors on somatotroph cells in the anterior pituitary gland. This targeted approach allows for precise stimulation of the body's natural growth hormone production pathways.

Upon binding to GHRH receptors (G-protein coupled receptors), tesamorelin triggers a well-characterised cascade: adenylyl cyclase activation increases cyclic adenosine monophosphate (cAMP) levels, which activates protein kinase A (PKA). This phosphorylates CREB (cAMP response element-binding protein), ultimately enhancing growth hormone gene transcription and triggering GH synthesis and release.

The released growth hormone then travels to the liver and peripheral tissues, binding to growth hormone receptors and stimulating IGF-1 production—the primary mediator of GH's effects. This includes enhanced lipolysis (particularly in visceral fat deposits), increased protein synthesis, and improved glucose metabolism.

Studies indicate that tesamorelin's effectiveness lies in what it doesn't disrupt. Unlike exogenous growth hormone, it preserves natural pulsatile release patterns and maintains feedback mechanisms. The hypothalamus can still regulate the system, preventing the desensitisation common with direct hormone replacement.

The peptide's structural modification—that trans-3-hexenoic acid group—protects it from rapid degradation by dipeptidyl peptidase-4 (DPP-4), extending its activity window. This is crucial because native GHRH has a half-life measured in minutes, whilst tesamorelin remains active for 26-38 minutes.

Research suggests that tesamorelin shows relative selectivity for visceral adipose tissue reduction compared to other GHRH analogues like Sermorelin. The exact mechanism behind this selectivity isn't fully understood but likely relates to tissue-specific receptor sensitivity and local IGF-1 production patterns. This targeted action explains why clinical trials have shown tesamorelin to be particularly effective for HIV lipodystrophy, where visceral fat accumulation is the primary concern.